The safety and cost-effectiveness of discontinuing disease-modifying therapies in stable relapsing-onset multiple sclerosis (DOT-MS): a randomized rater-blinded multicenter trial. - Discontinuation of disease modifying therapy in multiple sclerosis (DOT-MS)

Vrije Universiteit Medisch Centrum0 个研究点目标入组 130 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients who are treated with one of the first-line treatments (any of the
•interferons, glatiramer acetate, dimethylfumarate, teriflunomide) and who had a
•complete absence of inflammatory activity (no relapses, no new-T2 lesions and
•no contrast-enhancing lesions on MRI) for 5 consecutive years under first-line
•treatment will be eligible for inclusion. In case the last available MRI-scan
•was conducted 10 or more years ago, no more than 3 new T2-lesions in these 10
•years are accepted.

•- Clinical or radiological inflammatory disease activity in the 5 years prior
•to the study.
•- A switch between first-line disease modifying therapy over two years prior to
•inclusion, in case the switch has been due to in effectivity of the first DMT.
•In case the switch has been due to side-effects or by a personal preference of
•the patient (such as the wish to switch to oral therapies), this is not
•considered as an exclusion criterium.
•3. Women who want to discontinue medication because of a pregnancy wish and
•women who are pregnant or expect to become pregnant during the study period
•4. Patients that have previously used interferon-beta and have been tested
•positive for neutralizing antibodies (NAbs).

发起方